QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Often reclassification to Grade Group 2 from Grade Group 1 prostate cancer results in men leaving active surveillance. To date, there has been limited data available to guide this decision making. This study aimed to identify subgroups of men who…
This study examined the association of extraprostatic tumor extension (EPE) with biochemical recurrence (BCR) separately in men with Grade Group (GG)1 and Grade Group (GG)2 prostate cancer treated with radical prostatectomy. After review of patient records, a cohort of 6309…
The Veterans Choice Program (VCP), implemented in 2014, aimed to help veterans with prostate cancer get specialized care outside of Veterans Health Administration (VHA) facilities. This study examined how many veterans used this program and what kind of care they…
Researchers reported differences in the risk of early prostate cancer death among men with higher vs lower genetic risk. They performed a combined analysis with a 20-year follow-up of genotyped men without prostate cancer in 2 prospective cohort studies including…
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a PSA test. After 15 years of follow-up, prostate cancer-specific mortality was low in this cohort of men in the UK with…
Plant-based diets are associated with many benefits, including primary prevention of fatal prostate cancer. Less is known about post-diagnostic plant-based diet patterns in individuals with prostate cancer. This longitudinal observational cohort study included men with nonmetastatic prostate cancer. Data from…
Listen to the music. Dr. Catalona reflected upon his memory of one of his late patients and a member of the URF Board, Mr. Julius (Jules) Reichel, and his beloved grandson, Benjamin Sokol, who is now a rising star in…
A recent review article on BRCA1- and BRCA2- associated cancer risks and management of male patients updates and brings into focus information that has been covered far more extensively in the media than the risks for breast and ovarian cancer…
At the annual meeting of the Society of Urologic Oncology (SUO) held in the fall of 2023, Dr. Catalona gave an invited lecture to urologic oncologists on the Genetics of Prostate Cancer. This article is a condensation and simplification of…
A study, recently presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco found that high-risk prostate cancer patients benefit from dose-escalation radiotherapy in combination with long-term androgen deprivation therapy (ADT) with no increase in long-term…
"*" indicates required fields
